Index · Artikel · FDA staff question whether Aveo drug needs new trial

FDA staff question whether Aveo drug needs new trial

2013-04-30 0

résumén">Staff reviewers for the Food and Drug Administration have asked a panel of outside medical experts whether another clinical trial is needed before an experimental kidney cancer drug made by Aveo Pharmaceuticals Inc and Astellas Pharma Inc can b

n">Staff reviewers for the Food and Drug Administration have asked a panel of outside medical experts whether another clinical trial is needed before an experimental kidney cancer drug made by Aveo Pharmaceuticals Inc and Astellas Pharma Inc can be approved.

The question, posed in documents posted to the FDA's website on Tuesday, caused Aveo's shares to plummet as much as 26.7 percent on Nasdaq.

The reviewers noted that in a late-stage trial, patients taking the drug, tivozanib, did not live longer than those who took a rival product. They asked the panel to consider whether a new trial was needed to better assess risk versus benefit, given that other treatments are available.

The panel will discuss tivozanib, which is designed to treat patients with advanced renal cell cancer, on Thursday and advise the FDA on whether it should be approved based on the current available information.

A clinical trial of 517 patients showed that tivozanib delayed worsening of the disease by an average of 11.9 months compared with 9.1 months for Nexavar, a drug known generically as sorafenib that is made by Bayer AG and Onyx Pharmaceuticals. The result met the main goal of the trial.

Still, patients taking tivozanib did not, on average, live longer than those taking Nexavar. On average, patients in the tivozanib arm of the trial lived 28.8 months while patients taking sorafenib lived on average 29.3 months.

Drug industry analysts provided mixed interpretations of the reviewers' questions.

"We believe the tone of the briefing documents and the question posed to the panel are consistent with our prior work, where we were unable to find historical precedent of the FDA approving an agent with a detrimental overall survival trend," said Howard Liang, an analyst at Leerink Swann.

Salveen Richter, an analyst at Canaccord Genuity, concurred.

"We see considerable risk of a negative panel," he said in a research note.

Others were less pessimistic, saying that while the panel is likely to focus on the overall survival figures, the main goal of the trial was to show a statistically significant improvement in progression-free survival, the time before the disease worsens. The company achieved that goal.

In patients who had not previously received a similar therapy, tivozanib delayed worsening of disease by an average of 12.7 months.

"After review of the documents, we continue to believe there is a good likelihood of a favorable vote," said Geoff Meacham. "Net-net, we would be buyers ahead of the panel."

The trial showed that only 18 percent of tivozanib patients needed dosing interruptions due to side effects, compared with 35 percent for Nexavar. Patients taking tivozanib had a higher incidence of high blood pressure and fatigue, while those who received Nexavar in the study reported a higher incidence of diarrhea and hand-foot syndrome, a skin condition that resembles sunburn and can cause pain and swelling.

Advanced kidney cancer is the ninth most commonly diagnosed cancer in the United States, Aveo said, with an estimated 65,000 new cases projected to be diagnosed this year.

Tivozanib is a pill that is designed to block three members of the vascular endothelial growth factor (VEGF) family of proteins. Blocking VEGF acts to starve tumors of the blood supply and nutrients they need to survive.

The drug is also being studied in a range of other cancers, including metastatic colorectal cancer and metastatic breast cancer. Analysts on average expect the drug to generate annual sales of $1.23 billion by 2017.

In 2007, Aveo licensed the development and commercialization rights to tivozanib outside Asia from Kirin Brewery, now called Kyowa Hakko Kirin. Kyowa retained development and commercialization rights in Asia.

Four years later Aveo and Astellas agreed to co-develop tivozanib outside Asia. The two companies agreed to jointly share in the costs and profits of developing the drug in North America and Europe. Outside these regions, Astellas is responsible for development and commercialization costs and will pay Aveo royalties on sales in those territories.

Aveo's shares fell 26 percent in Tuesday afternoon trading to $5.48 on Nasdaq. Earlier they fell as low as $5.45.

(Reporting By Toni Clarke in Washington; editing by Sofina Mirza-Reid and Grant McCool)

FDA AVEO

FDA staff question whether Aveo drug needs new trial

n">Staff reviewers for the Food and Drug Administration have asked a panel of outside medical experts whether another clinical trial is needed before an experimental kidney cancer drug made by Aveo Pharmaceuticals Inc and Astellas Pharma Inc can b

2013-04-30 FDA AVEO
FDA staff question Pfizer arthritis drug benefits

WASHINGTON U.S. drug reviewers on Monday questioned whether the benefits of Pfizer Inc's experimental treatment for rheumatoid arthritis outweighed its risks of cancerous cells and infections. The Food and Drug Administration staff said the drug, cal

2012-05-07 FDA PFIZER
FDA staff question side effects of Regeneron gout drug

WASHINGTON U.S. drug reviewers said Regeneron Pharmaceuticals Inc's drug to prevent gout flares worked, but questioned its side effects and whether it did enough to help patients. The Food and Drug Administration staff on Friday said the injectable d

2012-05-04 FDA REGENERON
FDA staff question Novartis cystic fibrosis drug

WASHINGTON U.S. drug reviewers questioned whether Novartis AG's experimental inhaled antibiotic powder truly helped cystic fibrosis patients breathe better, according to documents posted by the Food and Drug Administration on its website Friday. The

2012-08-31 FDA NOVARTIS
FDA staff question efficacy of Merck's drug for infectious diarrhea

n">A preliminary regulatory review of Merck & Co Inc's experimental drug to treat the most common cause of infectious diarrhea often found in hospitals and nursing homes questioned whether the drug's efficacy had been adequately demonstrated.

2016-06-07 HEALTH MERCK CDIFFICILE
FDA staff question utility, trials of Novo Nordisk diabetes drug

n">A preliminary review by the U.S. Food and Drug Administration of Novo Nordisk A/S's experimental diabetes drug, IDegLira, questioned the interpretability of the study findings and practical use of the treatment, according to a review posted on

2016-05-20 DIABETES FDA NOVO NORDISK
FDA staff question usefulness of Sanofi diabetes drugs

n">A preliminary review by the U.S. Food and Drug Administration questioned the usefulness of a combination diabetes drug made by Sanofi SA's and said it was unclear whether one component, lixisenatide, contributed to its benefit. The French drugm

2016-05-23 DIABETES FDA SANOFI
FDA staff questions value of Vertex's cystic fibrosis combo

n">Staff reviewers from the U.S. FDA questioned whether Vertex Pharmaceuticals Inc's experimental combination therapy for cystic fibrosis had an added benefit over the company's already approved therapy, Kalydeco, in patients with the most common

2015-05-08 FDA PHARMS Vertex
U.S. FDA staff review of NPS drug sparks stock rebound

WASHINGTON Shares in NPS Pharmaceuticals Inc soared on Wednesday after a preliminary report from U.S. regulators said its hormone replacement therapy Natpara, which could be approved by late next month, appears to be effective. NPS shares rose 25 per

2014-09-10 Pharma NPS
Takeda colitis drug raises PML concern: FDA staff

n">An experimental drug for ulcerative colitis and Crohn's disease from Takeda Pharmaceutical Co could pose risk of a potentially fatal brain infection called PML even though the problem has not been seen in clinical trials, staff members of the U

2013-12-05 FDA Takeda ENTYVIO
FDA panel votes against Aveo's kidney cancer drug

n">An advisory panel to the Food and Drug Administration recommended that the agency reject a kidney cancer drug made by Aveo Pharmaceuticals Inc and Astellas Pharma Inc, saying data from the clinical trial were inconsistent. In a 13-1 vote on Thu

2013-05-02 AVEO ADVISORYPANEL
FDA staff flag safety fears over Sanofi MS drug Lemtrada

n">U.S. regulatory officials have raised concerns about "multiple serious and potentially fatal safety issues" in patients given Sanofi's new multiple sclerosis drug Lemtrada, fuelling uncertainty about whether it will be approved. Food

2013-11-08 SANOFI LEMTRADA
FDA staff review raises questions about MannKind diabetes device

WASHINGTON A review of MannKind Corp's experimental inhaled insulin device by U.S. Food and Drug Administration staff raised questions about its safety and effectiveness but was less damning than some investors had expected. The company's shares init

2014-03-28 MANNKIND
FDA staff raises no major concerns over Intercept's liver drug

n">The U.S. Food and Drug Administration's staff reviewers did not raise any major red flags over Intercept Pharmaceuticals Inc's liver drug on Tuesday, sending the stock up as much as 19 percent. The drug, obeticholic acid (OCA), is being reviewe

2016-04-05 FDA INTERCEPT
FDA staff posts voting questions for Teva's opioid painkiller

n">U.S. Food and Drug Administration staff released voting questions on Teva Pharmaceutical Industries Ltd's long-acting opioid painkiller for a panel of independent experts who will recommend to the agency whether to approve the drug. An FDA spok

2016-06-03 FDA TEVA PHARM IND
FDA staff focus on safety of Forest lung drug

WASHINGTON Drug reviewers said Forest Laboratories Inc and Almirall SA's inhaled lung treatment worked, but raised concerns about potential heart problems linked to drugs in the same class. Food and Drug Administration staff said on Tuesday the drug,

2012-02-21 FDA FOREST
FDA staff say two non-hormonal hot flashes drugs show some efficacy

n">Food and Drug Administration staff said experimental drugs by Depomed Inc and Hisamitsu Pharmaceutical Co Inc showed efficacy in reducing menopausal hot flashes, and highlighted no new risks in comments issued on Thursday. Depomed's shares rose

2013-02-28 FDA DEPOMED HISAMITSU
FDA staff finds no new safety problems with Glaxo's asthma drug

n">GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems while being tested to treat asthma, a preliminary review by U.S. Food and Drug Administration staff found. The review comes two days

2015-03-17 FDA GLAXOSMITHKLINE
Abbott may need more Humira studies: FDA staff

WASHINGTON Abbott Laboratories Inc may need to conduct additional trials of Humira to prove the blockbuster drug helps patients with ulcerative colitis, U.S. drug reviewers said on Friday. Staff from the U.S. Food and Drug Administration questioned w

2012-08-24 FDA ABBOTT
FDA staff say calcitonin salmon cancer risk appears plausible

n">Staff reviewers for the U.S. Food and Drug Administration said that a potential increased risk of cancer with drugs containing calcitonin salmon appears plausible. In briefing documents released on Friday, the reviewers said the risk raises con

2013-03-01 FDA Calcitonin

TOP

Day/
Week/
Original/
Recommand

Updated

Kann Valtrex mit Zithromax eingenommen werden?
Ich nehme Zithromax und Valtrex zugleich. Ist das schädlich oder kann man die andere aufheben? ----schneiden---- In Antwort auf die Marvell bei 2010-01-19 06.04 Ja, können Sie Valtrex und Zithromax zusammen nehmen. Es gibt keine bekannten Wechselwirk
Falsch-Positiv für PCP?!?
Mein Arzt hat mich auf Tramadol und hier vor kurzem war ich krank und musste Hustensaft mit Promethazin und azithrocine zu nehmen. Nun, ich landete mit ins Krankenhaus gebracht werden, weil, na ja, ich nicht genau, warum noch nicht. Sie sagen, dass e
Hat jemand fühlte 1 Tag gut und schlecht am nächsten, während effexor zu nehmen?
Mein Mann war unter 75 mg Effexor für 2 Jahre. Er hat vor kurzem auf 150 mg erhöht, weil jeden zweiten Tag ein guter / schlechter Tag war. Die 150mg erwies sich für ihn zu viel zu sein. Er ist nun wieder auf 75 mg, aber es scheint, dass jeden zweiten
Studie zeigt: Wer Hears Beste
Die Anhörung der Nation hat sich nicht allzu viel von 35 Jahren verändert vor, trotz der erheblichen Veränderungen in der Gesellschaft und Technologie. Eine neue Studie ergab auch, dass nicht-hispanischen Schwarzen besseres Hören im Durchschnitt im V
Wie eine laufende Gruppe zu finden
Wenn Sie schon immer von selbst zu betreiben, sind Sie nicht auf viele Vorteile von Gruppentraining aus, von einer verbesserten Motivation zu erweiterten sozialen Umfeld. Nicht sicher, wie über die Suche nach Menschen gehen mit zu laufen? Folge diese
Abbau der hohen C-reaktivem Protein
Die Reduzierung hohen C-reaktivem Protein im Blut die Entzündung zu verringern kann, was wiederum Ihre Darmkrebsrisiko senken kann. Hoch C-reaktiven Proteins signalisieren übermäßige Entzündung im Körper. Die Entzündung kann Ihr Risiko für viele chro
Hormon Orexin Kontrolle Gewichtszunahme Hilfe Mai, Studie fest,
Das Glück Freund von Ihnen - derjenige, der kaum Gewicht gewinnt, wenn die gleichen Dinge essen Sie essen, auch wenn Ihre Taille erweitert - vielleicht ein Hormon namens Orexin zu verdanken haben. Eine neue Studie zeigt, dass Mäuse in Orexin-Mangel,
Bauchschmerzen - Wenn man einen Arzt aufsuchen
Bauchschmerzen - Schmerzen oder Beschwerden im Bauchbereich - ist etwas, was uns alle früher oder später erfahren. Die meiste Zeit die Ursache der Bauchschmerzen relativ gutartig und selbstlimitierend. Manchmal aber gibt es eine schwerwiegende Erkran
Hashimoto-Krankheit - Kann mir jemand eine gute dr empfehlen. Im Bereich polis?
Gerade wurde vor kurzem diagnostiziert und auch mit chronischer Nesselsucht zu kämpfen. Kann nicht scheinen, eine gute dr zu finden. Um mir zu helfen mit hashi ist und Nesselsucht in der polis Bereich beschäftigen. Hilfe! ----schneiden---- In Antwort
Leben mit Demenz: Was ist nicht nett zu sagen, wenn Oma
Haben Sie eine Großeltern, Eltern, Onkel oder Freund mit der Alzheimer-Krankheit? Wenn ja, könnten Sie feststellen, ihr mehr vergesslich zu werden, mehr Mühe, die richtigen Worte zu finden, Ihnen etwas zu sagen, oder einige der anderen kognitiven Sym